UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts 83-2181531 (State or other ...

TransMedics Group, Inc. (NASDAQ:TMDX) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Brian Johnston - Vice President, Investor Relations Waleed Hassanein - President & Chief Executive Officer. Stephen Gordon - CFO, Treasurer & Secretary Conference Call Participants Cecilia Furlong - Morgan Stanley Josh Jennings - Cowen Bill Plovanic - Canaccord Mike Ott - Oppenheimer Operator Good afternoon, and welcome to TransMedics Second Quarter 2021 Earnings Conference Call. At this tim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts 83-2181531 (State or other jurisdiction of incorporation or organization) 200 Minuteman Road Andover, Massachusetts 01810 (Address of principal executive offices) (Zip code) (I.R.S. Employer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (978) 552-0900 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: For the transition period from to Commission File Number: 001-3 ...

Transmedics Group, Inc. (NASDAQ:TMDX) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Lynn Lewis - Gilmartin Group Waleed Hassanein - Founder, MD, CEO, President & Director Stephen Gordon - CFO, Treasurer & Secretary Conference Call Participants Cecilia Furlong - Morgan Stanley William Plovanic - Canaccord Genuity Suraj Kalia - Oppenheimer Operator Good afternoon and welcome to TransMedics' First Quarter 2021 Earnings Conference Call. [Operator Instructions]. I would now like t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of Registrant as specified in its Charter) Massachusetts 83-2181531 (State or other jurisd ...

TransMedics Group, Inc. (NASDAQ:TMDX) Q4 2020 Earnings Conference Call March 2, 2021 4:30 PM ET Company Participants Lynn Lewis – Investor Relations Waleed Hassanein – President and Chief Executive Officer Stephen Gordon – Chief Financial Officer Conference Call Participants David Lewis – Morgan Stanley Robbie Marcus – JP Morgan Suraj Kalia – Oppenheimer & Company Brian Kennedy – Cowen & Company Operator Ladies and gentlemen, thank you for standing by and welcome to TransMedics Q4 2020 Earnings Conference. ...

Financial Performance - Net revenue for the three months ended September 30, 2020, was $7,091,000, a slight decrease of 1.6% compared to $7,205,000 for the same period in 2019[20]. - Gross profit for the nine months ended September 30, 2020, was $11,807,000, an increase of 17% from $10,122,000 in the same period of 2019[20]. - The net loss for the three months ended September 30, 2020, was $5,088,000, an improvement from a net loss of $8,280,000 in the same period of 2019, indicating a reduction of 38.5%[22]. - For the fiscal nine months ended September 30, 2020, the net loss was $22,437 thousand, compared to a net loss of $24,370 thousand for the same period in 2019, indicating a reduction in losses[31]. - The Company generated net revenue of $18.0 million and incurred a net loss of $22.4 million for the fiscal nine months ended September 30, 2020, compared to a net revenue of $23.6 million and a net loss of $33.5 million for the fiscal year ended December 28, 2019[123]. Assets and Liabilities - Total assets increased to $159,322,000 as of September 30, 2020, up from $105,299,000 on December 28, 2019, representing a growth of 51.3%[17]. - The company had total liabilities of $49,772,000 as of September 30, 2020, a slight decrease from $50,650,000 on December 28, 2019, indicating a reduction of 1.7%[17]. - Total stockholders' equity rose to $109,550,000 as of September 30, 2020, compared to $54,649,000 on December 28, 2019, marking an increase of 100%[17]. - As of September 30, 2020, the company had cash, cash equivalents, and marketable securities totaling $132.7 million, expected to fund operations for at least the next 12 months[39]. Revenue Sources - The Company’s revenue is primarily generated from sales of organ-specific disposable sets and OCS Consoles, with additional revenue from rentals[54]. - OCS Heart net revenue increased to $5.427 million for the fiscal three months ended September 30, 2020, compared to $3.739 million in the same period in 2019, reflecting a growth of approximately 45.2%[71]. - Net revenue from customers in the United States increased by $1.579 million to $5.920 million for the fiscal three months ended September 30, 2020, while revenue from outside the U.S. decreased by $1.693 million to $1.171 million[157]. Operating Expenses - Operating expenses totaled $9,648,000 for the three months ended September 30, 2020, down from $11,458,000 in the same period of 2019, reflecting a decrease of 15.8%[20]. - Total operating expenses for the fiscal nine months ended September 30, 2020, were $32.295 million, an increase of $1.264 million compared to $31.031 million in 2019[165]. - Selling, general, and administrative expenses increased by $0.6 million to $18.0 million for the nine months ended September 30, 2020, mainly due to higher personnel costs[173]. Research and Development - Research and development expenses for the nine months ended September 30, 2020, were $14,283,000, an increase of 4.9% from $13,608,000 in the same period of 2019[20]. - Total research, development, and clinical trials expenses rose by $0.7 million to $14.3 million for the nine months ended September 30, 2020, driven by increased personnel and clinical trial costs[172]. Impact of COVID-19 - The COVID-19 pandemic has negatively impacted OCS product sales since Q2 2020, with anticipated continued effects for the remainder of 2020[42]. - The impact of the COVID-19 pandemic has resulted in significant disruptions to the company’s operations, including delays in clinical trials and transplant procedures[128]. - Recovery in transplant procedures has been observed, but activity levels have not yet returned to pre-pandemic levels[131]. Financing and Capital Structure - Proceeds from the issuance of common stock in the public offering, net of underwriting discounts and commissions, amounted to $75,670 thousand, compared to $97,367 thousand in the previous year[31]. - The Company completed an underwritten public offering on May 26, 2020, resulting in net proceeds of approximately $75.0 million after deducting offering costs[126]. - The company has authorized up to 150 million shares of common stock, with no dividends declared or paid as of September 30, 2020[97]. Future Outlook - The company expects long-term net revenue growth driven by FDA approvals for OCS products and increased non-U.S. sales[141]. - The company expects costs and expenses to increase as it expands its sales and clinical adoption team, scales manufacturing operations, and continues research and development efforts[193]. - The company believes existing cash, cash equivalents, and marketable securities will fund operating expenses and capital expenditures for at least 12 months following the filing of the Quarterly Report[195].

TransMedics Group, Inc. (NASDAQ:TMDX) Q3 2020 Earnings Conference Call November 4, 2020 4:30 AM ET Company Participants Brian Johnston – Vice President, Investor Relations- Gilmartin Group Waleed Hassanein – President and Chief Executive Officer Stephen Gordon – Chief Financial Officer Conference Call Participants Cecilia Furlong – Morgan Stanley Allen Gong – J.P. Morgan Suraj Kalia – Oppenheimer & Company Brian Kennedy – Cowen Operator Ladies and gentlemen, thank you for standing by, and welcome to the Tra ...

TransMedics Group, Inc. (NASDAQ:TMDX) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Brian Johnston - Vice President, Investor Relations-Gilmartin Group Waleed Hassanein - President & Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Suraj Kalia - Oppenheimer Josh Jennings - Cowen & Company Operator Good afternoon, everyone. Thank you for standing by and welcome to the TransMedics Q2 2020 Earnings Conference Call. At this time, all ...